Fed’s Powell opens door to potential rate cuts at Jackson Hole
SAN FRANCISCO—Hims & Hers Health, Inc. (NYSE:HIMS) reported that Irene Becklund, the company’s Principal Accounting Officer, sold 2,203 shares of Class A Common Stock on March 11, 2025. The shares were sold at an average price of $34.77 each, resulting in a total transaction value of $76,598.
The sale was conducted under a Rule 10b5-1 trading plan, which was adopted by Becklund on August 7, 2024. Following this transaction, Becklund retains ownership of 2,203 shares in the company. InvestingPro subscribers can access 14 additional investment tips and comprehensive analysis for HIMS, including detailed insider trading patterns and valuation metrics.
In addition to the sale, Becklund acquired 22,284 Restricted Stock Units (RSUs) on the same date. Each RSU represents a contingent right to receive one share of Class A Common Stock. These RSUs are subject to a service-based vesting schedule, with the first vesting date set for June 15, 2025, followed by quarterly vesting thereafter. The company has demonstrated strong momentum, with shares up nearly 105% over the past six months.
In other recent news, Hims & Hers Health, Inc. has been the focus of multiple analyst updates and regulatory developments. BofA Securities reiterated its Underperform rating with a $21.00 price target, following the FDA’s extension of enforcement timelines for the compounding of semaglutide, a key medication for the company, until 2025. This provides a temporary regulatory framework for Hims & Hers, as the company navigates the evolving landscape. Citi also maintained a Sell rating with a $27.00 price target, highlighting ongoing legal challenges related to tirzepatide, another medication impacting the industry. The legal proceedings have sparked concerns about the potential implications for Hims & Hers, especially if similar rulings affect semaglutide compounding.
Despite the challenges, BofA Securities projects that Hims & Hers will generate over $200 million in revenue from GLP-1 products in the first quarter of 2025, with a total of $725 million expected from weight loss products for the year. However, both BofA and Citi express caution, noting that increased competition and regulatory scrutiny could impact the company’s ability to meet these revenue targets. Analysts from both firms remain skeptical about the company’s near-term growth prospects, given the uncertainties in the regulatory environment and market dynamics. These recent developments continue to shape investor sentiment toward Hims & Hers.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.